Multimodal Therapy Impact on Pancreatic Cancer Survival

Survival Outcome Analysis on the Strategy Shift Integrating a Multimodal Therapy of Neoadjuvant Chemotherapy and Extended Pancreatectomy in Pancreatic Cancer: A Clinical Study From a Retrospective Cohort in a Single Institute

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06938906

Acronym

MMTIPS

Enrollment

405

Registered

2025-04-22

Start date

2011-01-03

Completion date

2025-04-30

Last updated

2025-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoadjuvant Chemotherapy, Pancreatectomy, Pancreatic Cancer

Keywords

pancreatic cancer, neoadjuvant chemotherapy, extended pancreatectomy, multimodal therapy, paradigm shift, survival outcomes

Brief summary

The goal of this retrospective cohort study is to analyze change of treatment strategies affect the survival outcomes in patients of pancreatic cancer who received curative-intent treatment. The main question it aims to answer is: Hypothesis: Change of treatment strategies involving increased utility of neoadjuvant chemotherapy and aggressive surgical approaches of extended pancreatectomy improved the overall and progression free survival in the patients with pancreatic cancer. Participants received curative treatment for pancreatic cancer.

Detailed description

This study is to analyze the change of treatment strategies and shift of the paradigm over time in a single center. Researchers plan to see the impact of the evolvement to the survival outcomes in pancreatic cancer.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pancreatic adenocarcinoma * Received curative surgery

Exclusion criteria

* Other subtypes of pancreatic cancer including acinar cell carcinoma, mucinous carcinoma, undifferentiated carcinoma and intraductal papillary mucinous neoplasm with associated adenocarcinoma * Cases with palliative or R2 resection were also excluded from the analysis.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival and Progression-free survival	From enrollment to two years after the end of treatment	Overall survival was calculated from the first treatment day of the disease to the day of mortality. Progression-free survival was calculated from the first treatment day of the disease to the day of proression or recurrece of pancreatic cancer.

Countries

Taiwan

Outcome results